Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351593 · ClinicalTrials.gov registry record · Phase 1
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
A Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, sponsored by James Rubenstein.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05351593 is a Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma that is actively recruiting participants, run by James Rubenstein. The registered enrollment target is 35 participants, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05351593, a Phase 1 study of Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by James Rubenstein.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that Tafasitamab enhances blood-brain barrier permeability, a potential property that could have broad clinical implications.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Tafasitamab
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05351593
The ClinicalTrials.gov registry entry for NCT05351593 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (30% lower). The listed sponsor is James Rubenstein, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05351593 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05351593 about?
NCT05351593 is a clinical study titled "Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma". This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the comb...
What is the current status of trial NCT05351593?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2022-06-08. Estimated completion is 2026-06-30.
What conditions does trial NCT05351593 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, CNS Lymphoma.
What interventions are being tested in trial NCT05351593?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT05351593?
This trial is sponsored by James Rubenstein, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05351593 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
RECRUITING · Phase 1
-
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
RECRUITING · Phase 1
-
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
RECRUITING · Phase 1
-
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Primary Central Nervous System Lymphoma
All registered trials for this condition
Secondary Central Nervous System Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.